Type:
Educational Exhibit
Keywords:
Neuroradiology brain, MR, Diagnostic procedure, Dementia, Genetic defects
Authors:
L. T. Semeniuk, J. Y. Wang, A. Elias, F. Tassone, D. Hessl, S. M. Rivera, R. J. Hagerman
DOI:
10.26044/ecr2023/C-17418
Personal information and conflict of interest
L. T. Semeniuk:
Nothing to disclose
J. Y. Wang:
Nothing to disclose
A. Elias:
Nothing to disclose
F. Tassone:
Other: funding from Zynerba and the Azrieli Foundation to carry out molecular studies in fragile X syndrome. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
D. Hessl:
Other: Provides consultation to Healx and Tetra Pharmaceutical companies regarding assessment and treatment of fragile X syndrome. He is a member of the Clinical Trials Committee and the Scientific and Clinical Advisory Board of the National Fragile X Foundation.
S. M. Rivera:
Nothing to disclose
R. J. Hagerman:
Other: Received funding from Zynerba, Ovid, and the Azrieli Foundation to carry out treatment studies in fragile X syndrome, and has also consulted with Zynerba and Fulcrum regarding treatment studies in fragile X syndrome